Alexithymia More Common in Adolescents With Cystic Fibrosis, and Linked to Worse Lung Function

Fatih Ercan, Sevgi Pekcan, Semih Erden, et al.

Summary: This Turkish cross-sectional study compared alexithymia scores — measured by the validated Toronto Alexithymia Scale (TAS-20) — between adolescents aged 14–18 with cystic fibrosis and age-matched healthy controls. Patients with CF scored significantly higher on the TAS-20, indicating greater difficulty identifying and describing emotional states. A statistically significant negative correlation was observed between TAS-20 scores and FEV1, suggesting that more severe alexithymia tracks with worse pulmonary function.

Why it matters: Alexithymia — the reduced capacity to recognize and articulate one's own emotions — is associated in other chronic illness populations with poorer treatment adherence, worse quality of life, and suboptimal engagement with psychosocial support. If elevated alexithymia is genuinely more prevalent in CF adolescents and correlates with declining lung function, it could represent an underrecognized barrier to self-management, adherence to complex treatment regimens, and effective communication with care teams. The study raises a reasonable clinical question: are multidisciplinary CF teams adequately screening for emotional processing difficulties, especially in adolescents who are clinically deteriorating?

Expert perspective: The research question is legitimate and clinically relevant, and the use of a validated instrument (TAS-20) is appropriate. However, several limitations should temper interpretation. First, cross-sectional design prevents any causal inference: it cannot be determined whether alexithymia contributes to worse pulmonary outcomes, whether worsening illness fosters emotional blunting as a coping response, or whether both reflect a common underlying vulnerability. The negative correlation between TAS-20 scores and FEV1 is intriguing but is equally consistent with all three possibilities. Second, the sample is adolescent-only, limiting generalizability to younger children or adults with CF. Third, the abstract does not report the sample size — a notable gap in a rare disease population with a narrow age window, where small numbers could meaningfully inflate the risk of a Type I error. Fourth, the healthy control comparison does not account for the emotional burden of any serious chronic illness; a comparison with adolescents managing other chronic conditions would have strengthened the specificity of the finding to CF. Fifth, important confounders — including socioeconomic status, family functioning, mental health comorbidities, and access to psychosocial support — are not described in the available abstract. The authors' recommendation for integrated psychiatric support within multidisciplinary CF care is clinically sensible and consistent with existing CF foundation guidelines, but this recommendation predates the current study and does not depend solely on its findings. Overall, this is useful preliminary evidence that identifies alexithymia as worthy of systematic clinical attention in CF, but the findings are best treated as hypothesis-generating rather than practice-changing.

Relevance: Cystic Fibrosis

Source: https://pubmed.ncbi.nlm.nih.gov/42631608/

---